📊 HIND Key Takeaways
Is HIND a Good Investment? Thesis Analysis
Vyome Holdings exhibits an unsustainable business model with $10.3M annual net losses against only $319.7K in revenue, requiring 30+ years of current growth just to break even. Despite healthy 68.4% gross margins and 24.4% revenue growth, the company is burning $3.7M in operating cash annually with only $5M cash reserves, providing approximately 1.4 years of runway. The massive operating expense base relative to revenue scale indicates fundamental business model challenges requiring significant operational restructuring.
Why Buy HIND? Key Strengths
- Strong gross margin of 68.4% demonstrates viable product economics and pricing power
- Positive revenue growth of 24.4% YoY indicates market demand for offerings
- Adequate short-term liquidity with current ratio of 1.99x and $5M cash reserve
HIND Investment Risks to Consider
- Catastrophic operating losses of $10.3M against $319.7K revenue represents structurally unsustainable economics
- Negative operating cash flow of $3.7M annually with limited cash runway of ~1.4 years at current burn rate
- Disproportionately high operating expenses with no credible path to profitability; would require 30x+ revenue growth to break even
- Zero insider buying activity in 90 days suggests lack of confidence from management
- Company operates as development-stage entity with minimal commercial traction relative to overhead
Key Metrics to Watch
- Operating cash burn rate and cash runway (critical survival metric)
- Revenue growth acceleration required to approach break-even economics
- Operating expense reduction initiatives and cost structure management
HIND Financial Metrics
💡 AI Analyst Insight
Vyome Holdings, Inc presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
HIND Profitability Ratios
HIND vs Healthcare Sector
How Vyome Holdings, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HIND Overvalued or Undervalued?
Based on fundamental analysis, Vyome Holdings, Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HIND Balance Sheet & Liquidity
HIND 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Vyome Holdings, Inc's revenue has grown significantly by 164% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6,001.39 indicates the company is currently unprofitable.
HIND Growth Metrics (YoY)
HIND Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $1.2M | -$1.2M | $-1.85 |
| Q1 2025 | $1.1M | $1.5M | $18.98 |
| Q3 2024 | $2.2M | -$1.6M | $-3.11 |
| Q2 2024 | $2.0M | -$1.6M | $-0.06 |
| Q1 2024 | $1.9M | -$2.2M | $-0.09 |
| Q3 2023 | $2.2M | -$3.5M | $-1.02 |
| Q2 2023 | $2.3M | -$3.5M | $-1.08 |
| Q1 2023 | $2.3M | -$2.7M | $-1.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HIND Capital Allocation
HIND SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Vyome Holdings, Inc (CIK: 0001427570)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HIND
What is the AI rating for HIND?
Vyome Holdings, Inc (HIND) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HIND's key strengths?
Claude: Strong gross margin of 68.4% demonstrates viable product economics and pricing power. Positive revenue growth of 24.4% YoY indicates market demand for offerings.
What are the risks of investing in HIND?
Claude: Catastrophic operating losses of $10.3M against $319.7K revenue represents structurally unsustainable economics. Negative operating cash flow of $3.7M annually with limited cash runway of ~1.4 years at current burn rate.
What is HIND's revenue and growth?
Vyome Holdings, Inc reported revenue of $319.7K.
Does HIND pay dividends?
Vyome Holdings, Inc does not currently pay dividends.
Where can I find HIND SEC filings?
Official SEC filings for Vyome Holdings, Inc (CIK: 0001427570) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HIND's EPS?
Vyome Holdings, Inc has a diluted EPS of $-4.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HIND a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vyome Holdings, Inc has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HIND stock overvalued or undervalued?
Valuation metrics for HIND: ROE of -272.8% (sector avg: 15%), net margin of -3,209.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HIND stock in 2026?
Our dual AI analysis gives Vyome Holdings, Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HIND's free cash flow?
Vyome Holdings, Inc's operating cash flow is $-3.7M, with capital expenditures of $43.0K. FCF margin is -1,186.0%.
How does HIND compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,209.7% (avg: 12%), ROE -272.8% (avg: 15%), current ratio 1.99 (avg: 2).